Revolutionizing Hepatic Disease Management: Emerging Biologics, Regenerative Strategies, and Next-Generation Antifibrotics in Liver Therapy and Diagnosis
DOI:
https://doi.org/10.64261/8djy8k49Keywords:
Hepatic disease, Biologic therapies, Regenerative medicine, Antifibrotic agents, Liver fibrosis.Abstract
Hepatic diseases constitute one of the leading health problems in the world, as they pose a significant morbidity and mortality rates, as they are progressive, and have few treatment options in their advanced phases. Other disorders which include metabolic dysfunction-associated steatohepatitis, hepatitis viral, cirrhosis, and hepatocellular carcinoma usually have no symptoms and are usually diagnosed at later stages when they become difficult to treat. The latest developments in biomedical studies have also brought new treatment methods that would alter the course of the disease instead of simply controlling the symptoms. More recent biologic agents are monoclonal antibodies, cytokine modulators, and gene-based interventions, which target molecular pathways of inflammation, impaired immune regulation and fibrosis, which are specific. Simultaneously, regenerative medicine including stem cell therapy, liver organoids and bioartificial liver systems have potential solutions to all aspects of hepatic reconstruction of structure and functioning. Moreover, there is the development of next-generation antifibrotic agents such as HDAC inhibitor, RNA-based therapeutics, and novel small molecule to block fibrogenesis and induce fibrosis reversal. Improvement of non-invasive devices of diagnosis and imaging techniques also contribute to early diagnosis and individual treatment plans. Taken together, these advances point to a revolution of the integrated, regenerative and precision-based approach to the treatment of liver diseases
References
1. Guo, Z., et al., Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021. Scientific Reports, 2025. 15(1): p. 7083.
2. Wazir, H., et al., Diagnosis and treatment of liver disease: current trends and future directions. Cureus, 2023. 15(12).
3. Wu, Y., et al., Nanomaterials for Targeting Liver Disease: Research Progress and Future Perspectives. Nano Biomedicine & Engineering, 2023. 15(2).
4. Overi, D., et al., Hepatocyte injury and hepatic stem cell niche in the progression of non-alcoholic steatohepatitis. Cells, 2020. 9(3): p. 590.
5. Gan, C., et al., Liver diseases: epidemiology, causes, trends and predictions. Signal Transduct Target Ther, 2025. 10(1): p. 33.
6. Pinter, M., et al., Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open, 2016. 1(2): p. e000042.
7. Williams, R., et al., Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. The Lancet, 2014. 384(9958): p. 1953-1997.
8. Lazarus, J.V., et al., Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology & Hepatology, 2022. 19(1): p. 60-78.
9. Muthiah, M.D., N. Cheng Han, and A.J. Sanyal, A clinical overview of non‐alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications—what the non‐specialist needs to know. Diabetes, Obesity and Metabolism, 2022. 24: p. 3-14.
10. Cotter, T.G. and M. Rinella, Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology, 2020. 158(7): p. 1851-1864.
11. Fernandez, C.J., et al., Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink. Pathogens, 2024. 13(1).
12. EASL Clinical Practice Guidelines: Liver transplantation. Journal of Hepatology, 2016. 64(2): p. 433-485.
13. Rauth, S., et al., Recent advances in organoid development and applications in disease modeling. Biochim Biophys Acta Rev Cancer, 2021. 1875(2): p. 188527.
14. Neshat, S.Y., et al., Liver disease: induction, progression, immunological mechanisms, and therapeutic interventions. International journal of molecular sciences, 2021. 22(13): p. 6777.
15. Żurawek, M., I. Ziółkowska-Suchanek, and K. Iżykowska, Fibrosis in Immune-Mediated and Autoimmune Disorders. Journal of Clinical Medicine, 2025. 14(18): p. 6636.
16. Pires, I.S., P.T. Hammond, and D.J. Irvine, Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress. Advanced therapeutics, 2021. 4(8): p. 2100035.
17. Wang, L., F.S. Wang, and M.E. Gershwin, Human autoimmune diseases: a comprehensive update. Journal of internal medicine, 2015. 278(4): p. 369-395.
18. Mach, J.-P., Introduction to monoclonal antibodies. Cancer Immunity, 2012. 12(1): p. 11.
19. Pierpont, T.M., C.B. Limper, and K.L. Richards, Past, present, and future of rituximab—the world’s first oncology monoclonal antibody therapy. Frontiers in oncology, 2018. 8: p. 163.
20. Mease, P.J., Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert opinion on biological therapy, 2005. 5(11): p. 1491-1504.
21. Sparrow, E., et al., Therapeutic antibodies for infectious diseases. Bulletin of the World Health Organization, 2017. 95(3): p. 235.
22. Rider, P., Y. Carmi, and I. Cohen, Biologics for targeting inflammatory cytokines, clinical uses, and limitations. International journal of cell biology, 2016. 2016(1): p. 9259646.
23. Mulholland, M., et al., Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation. Cardiovascular Research, 2024. 120(6): p. 581-595.
24. Xiang, Y., et al., The role of inflammation in autoimmune disease: a therapeutic target. Frontiers in immunology, 2023. 14: p. 1267091.
25. Phillips, M.I. and Y.L. Tang, Genetic modification of stem cells for transplantation. Advanced drug delivery reviews, 2008. 60(2): p. 160-172.
26. Potrykus, I., Gene transfer to plants: assessment of published approaches and results. Annual review of plant physiology and plant molecular biology, 1991. 42(1): p. 205-225.
27. Weisberg, S.M., D. Badgio, and A. Chatterjee, A CRISPR new world: attitudes in the public toward innovations in human genetic modification. Frontiers in public health, 2017. 5: p. 117.
28. Martínez, T., et al., Silencing human genetic diseases with oligonucleotide-based therapies. Human genetics, 2013. 132(5): p. 481-493.
29. Braga, L.A.M., C.G. Conte Filho, and F.B. Mota, Future of genetic therapies for rare genetic diseases: what to expect for the next 15 years? Therapeutic advances in rare disease, 2022. 3: p. 26330040221100840.
30. Pinyopornpanish, K., et al., Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut and liver, 2021. 15(6): p. 827.
31. Del Campo, J.A., P. Gallego, and L. Grande, Role of inflammatory response in liver diseases: Therapeutic strategies. World journal of hepatology, 2018. 10(1): p. 1.
32. Ramadori, G., et al., Physiology and pathophysiology of liver inflammation, damage and repair. J Physiol pharmacol, 2008. 59(Suppl 1): p. 107-117.
33. Li, D. and S. Friedman, Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. Journal of gastroenterology and hepatology, 1999. 14(7): p. 618-633.
34. Cantz, T., M.P. Manns, and M. Ott, Stem cells in liver regeneration and therapy. Cell and tissue research, 2008. 331(1): p. 271-282.
35. Pinyopornpanish, K., et al., Secondary iron overload and the liver: a comprehensive review. Journal of Clinical and Translational Hepatology, 2023. 11(4): p. 932.
36. Zhou, D. and J. Fan, Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction. Chinese Medical Journal, 2024. 137(22): p. 2687-2696.
37. Kudo, M., et al., Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis. Liver Cancer, 2025.
38. Lok, A.S., Toward a functional cure for hepatitis B. Gut and liver, 2024. 18(4): p. 593.
39. Liu, C.H., et al., Resmetirom and Thyroid Hormone Receptor‐Targeted Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD). Portal hypertension & cirrhosis, 2025. 4(1): p. 66-78.
40. Yang, X., et al., Mesenchymal stem cell therapy for liver disease: full of chances and challenges. Cell & bioscience, 2020. 10(1): p. 123.
41. Yang, C., et al., Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nature reviews Gastroenterology & hepatology, 2023. 20(4): p. 203-222.
42. Zhang, Z. and F.-S. Wang, Stem cell therapies for liver failure and cirrhosis. Journal of Hepatology, 2013. 59(1): p. 183-185.
43. Wang, J., et al., Stem cell-based therapies for liver diseases: an overview and update. Tissue engineering and regenerative medicine, 2019. 16(2): p. 107-118.
44. Hu, C., Z. Wu, and L. Li, Mesenchymal stromal cells promote liver regeneration through regulation of immune cells. International journal of biological sciences, 2020. 16(5): p. 893.
45. Kholodenko, I.V., et al., Mesenchymal stem cells in the adult human liver: hype or hope? Cells, 2019. 8(10): p. 1127.
46. Lin, S., et al., A comprehensive meta-analysis of stem cell therapy for liver failure: Assessing treatment efficacy and modality. Annals of Hepatology, 2025. 30(2): p. 101586.
47. Tsuchiya, A., et al., Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration. Inflammation and regeneration, 2019. 39(1): p. 18.
48. Lee, C., et al., Mesenchymal stem cells influence activation of hepatic stellate cells, and constitute a promising therapy for liver fibrosis. Biomedicines, 2021. 9(11): p. 1598.
49. Zhong, C., et al., Tumorigenicity risk of iPSCs in vivo: nip it in the bud. Precis Clin Med, 2022. 5(1): p. pbac004.
50. Gu, J., et al., Systematic review: extracorporeal bio-artificial liver-support system for liver failure. Hepatology international, 2012. 6(4): p. 670-683.
51. Brown Jr, R.S., et al., Artificial liver support systems in acute liver failure and acute-on-chronic liver failure: Systematic review and meta-analysis. Critical Care Explorations, 2025. 7(1): p. e1199.
52. GUO, D., X. XIA, and J. YANG, Three-dimensional cell-based strategies for liver regeneration. BIOCELL, 2024. 48(7): p. 1023--1036.
53. van de Kerkhove, M.P., et al., Clinical application of bioartificial liver support systems. Ann Surg, 2004. 240(2): p. 216-30.
54. Br, V.K. and S.K. Sarin, Acute-on-chronic liver failure: Terminology, mechanisms and management. Clin Mol Hepatol, 2023. 29(3): p. 670-689.
55. Harrison, S.P., et al., Liver organoids: recent developments, limitations and potential. Frontiers in medicine, 2021. 8: p. 574047.
56. Yamaguchi, H., et al., Reversal of ACLF and ALF using whole blood extracorporeal system combining HLA-depleted liver organoids with granulocyte-monocyte apheresis. Journal of Hepatology, 2025.
57. Nair, D.G. and R. Weiskirchen, Recent advances in liver tissue engineering as an alternative and complementary approach for liver transplantation. Current Issues in Molecular Biology, 2023. 46(1): p. 262-278.
58. da Silva Morais, A., et al., Advanced biomaterials and processing methods for liver regeneration: state‐of‐the‐art and future trends. Advanced healthcare materials, 2020. 9(5): p. 1901435.
59. Ye, S., et al., Hydrogels for liver tissue engineering. Bioengineering, 2019. 6(3): p. 59.
60. Mohebbi, S., et al., Chitosan in biomedical engineering: a critical review. Current stem cell research & therapy, 2019. 14(2): p. 93-116.
61. Liu, H., et al., Advances in Hydrogels in Organoids and Organs‐on‐a‐Chip. Advanced Materials, 2019. 31(50): p. 1902042.
62. Lauschke, V.M., et al., 3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications. Biotechnology journal, 2019. 14(7): p. 1800347.
63. Li, W., et al., Application of 3D bioprinting in liver diseases. Micromachines, 2023. 14(8): p. 1648.
64. Fu, J., H. Qiu, and C.S. Tan, Microfluidic liver-on-a-chip for preclinical drug discovery. Pharmaceutics, 2023. 15(4): p. 1300.
65. Jangra, A., et al., Recent advancements in antifibrotic therapies for regression of liver fibrosis. Cells, 2022. 11(9): p. 1500.
66. Xu, X., et al., Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7-mediated degradation of TGFβRI. Liver Int, 2023. 43(11): p. 2523-2537.
67. Zheng, L., et al., The role of HDAC6 in fibrosis: a novel and effective therapy strategy. Eur J Med Res, 2025. 30(1): p. 571.
68. Zhang, C., et al., Nanoparticle-mediated RNA therapy attenuates nonalcoholic steatohepatitis and related fibrosis by targeting activated hepatic stellate cells. ACS nano, 2023. 17(15): p. 14852-14870.
69. Zhao, X., et al., Targeting metabolic dysregulation for fibrosis therapy. Nature reviews Drug discovery, 2020. 19(1): p. 57-75.
70. Shi, M., et al., Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatology International, 2021. 15(6): p. 1431-1441.
71. Claveria-Cabello, A., et al., Epigenetics in liver fibrosis: could HDACs be a therapeutic target? Cells, 2020. 9(10): p. 2321.
72. Borrello, M.T., et al., Pharmacological manipulation of liver fibrosis progression using novel HDAC6 inhibitors. Febs j, 2025. 292(13): p. 3397-3411.
73. Samuvel, D.J., et al., LP340, a novel histone deacetylase inhibitor, decreases liver injury and fibrosis in mice: role of oxidative stress and microRNA-23a. Frontiers in Pharmacology, 2024. 15: p. 1386238.
74. Hancock, W., et al., HDAC inhibitor therapy in autoimmunity and transplantation. Annals of the rheumatic diseases, 2012. 71 Suppl 2: p. i46-54.
75. López, A., et al., Development of Novel Antifibrotic Agents for Treating Progressive Liver Fibrosis and Related Complications. 2024.
76. Daliri, K., Developing a Gene Editing Strategy to Target the COL1A1 Promoter: Significance for Fibrotic Disorders and Pioneering Beyond the Boundaries of CRISPRi System. 2024, Universität zu Köln.
77. Maiers, J., et al., The Unfolded Protein Response Mediates Fibrogenesis and Collagen I Secretion Through Regulating TANGO1 in Mice. Hepatology, 2017. 65: p. 983-998.
78. Han, X., et al., Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nature Communications, 2023. 14.
79. Yang, T., et al., Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. Journal of hepatology, 2021. 75(6): p. 1420-1433.
80. Diwan, R., et al., Liver fibrosis pathologies and potentials of RNA based therapeutics modalities. Drug Delivery and Translational Research, 2024. 14(10): p. 2743-2770.
81. Liu, Y., et al., Targeted drug delivery strategies for the treatment of hepatocellular carcinoma. Molecules, 2024. 29(18): p. 4405.
82. Chen, Z., Discovery of peptide and aptamer ligands for targeted drug delivery to hepatic stellate cells. 2016: University of Missouri-Kansas City.
83. Henkel, A.S., et al., Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice. Hepatol Commun, 2018. 2(12): p. 1479-1492.
84. Pei, Q., Q. Yi, and L. Tang, Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities. International journal of molecular sciences, 2023. 24(11): p. 9671.
85. Lee, J.C.C., Identifying novel epigenetic regulators of non-alcoholic fatty liver disease using in vivo RNAi screening. 2025, Nanyang Technological University.
86. Sepúlveda-Crespo, D., S. Resino, and I. Martínez, Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs, 2021. 81.
87. Di, X., et al., Targeting fibrosis: from molecular mechanisms to advanced therapies. Advanced Science, 2025. 12(3): p. 2410416.
88. Yu, X., et al., TGF-β. Applications of Herbal Medicine to Control Chronic Kidney Disease: Volume II, 2023. 16648714: p. 30.
89. Stamenkovic, I., Extracellular matrix remodelling: the role of matrix metalloproteinases. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2003. 200(4): p. 448-464.
90. Strzelec, M., et al., Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Frontiers in immunology, 2023. 14: p. 1127704.
91. Collins, A.L., The development of hepatocellular carcinoma models in precision-cut tissue slices for therapeutic screening and precision medicine. 2024, Newcastle University.
92. Shan, L., et al., New Drugs for Hepatic Fibrosis. Front Pharmacol, 2022. 13: p. 874408.
93. Lachenmayer, A., et al., Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol, 2012. 56(6): p. 1343-50.
94. Patel, K., P. Bedossa, and L. Castera. Diagnosis of liver fibrosis: present and future. in Seminars in liver disease. 2015. Thieme Medical Publishers.
95. Hauge, A. and E.K. Rofstad, Antifibrotic therapy to normalize the tumor microenvironment. Journal of translational medicine, 2020. 18(1): p. 207.
96. Yang, F., et al., Next-generation of selective histone deacetylase inhibitors. RSC Adv, 2019. 9(34): p. 19571-19583.
97. Abdellatif, A.A., et al., Nano-scale delivery: A comprehensive review of nano-structured devices, preparative techniques, site-specificity designs, biomedical applications, commercial products, and references to safety, cellular uptake, and organ toxicity. Nanotechnology Reviews, 2021. 10(1): p. 1493-1559.
98. Jelliffe, R.W., et al., Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Therapeutic drug monitoring, 1993. 15(5): p. 380-393.
99. Serrano, D.R., et al., Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics, 2024. 16(10).
100. Mardpour, S., et al., Hydrogel-mediated sustained systemic delivery of mesenchymal stem cell-derived extracellular vesicles improves hepatic regeneration in chronic liver failure. ACS applied materials & interfaces, 2019. 11(41): p. 37421-37433.
101. Wang, X.X., et al., The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice. J Biol Chem, 2022. 298(11): p. 102530.
102. Nainggolan, A.D.C., et al., Microneedle-Mediated Transdermal Delivery of Genetic Materials, Stem Cells, and Secretome: An Update and Progression. Pharmaceutics, 2023. 15(12).
103. Day, D. and L.L. Siu, Approaches to modernize the combination drug development paradigm. Genome medicine, 2016. 8(1): p. 115.
104. Sánchez-Valle, V., et al., Role of oxidative stress and molecular changes in liver fibrosis: a review. Current medicinal chemistry, 2012. 19(28): p. 4850-4860.
105. Zhang, D., Y. Zhang, and B. Sun, The molecular mechanisms of liver fibrosis and its potential therapy in application. International journal of molecular sciences, 2022. 23(20): p. 12572.
106. Kholodenko, I.V. and K.N. Yarygin, Cellular mechanisms of liver regeneration and cell‐based therapies of liver diseases. BioMed research international, 2017. 2017(1): p. 8910821.
107. Dong, Q., et al., Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies. Frontiers in Medicine, 2023. 10: p. 1120621.
108. Roehlen, N., E. Crouchet, and T.F. Baumert, Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells, 2020. 9(4): p. 875.
109. Makri, E.S., E. Makri, and S.A. Polyzos, Combination therapies for nonalcoholic fatty liver disease. Journal of personalized medicine, 2022. 12(7): p. 1166.
110. Zhu, X.J., et al., Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co-Inhibition of TGF-β and GSK-3 Signalling. Liver Int, 2025. 45(7): p. e70187.
111. Nasir, S.A., et al., Advances in Novel Drug Therapy for Metabolic Dysfunction-associated Steatohepatitis Cirrhosis. Journal of Translational Gastroenterology, 2025. 3(1): p. 9-17.
112. Ramanathan, R., et al., Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation, 2014. 98(1): p. 100-6.
113. Bansal, R., B. Nagórniewicz, and J. Prakash, Clinical advancements in the targeted therapies against liver fibrosis. Mediators of inflammation, 2016. 2016(1): p. 7629724.
114. Puengel, T. and F. Tacke, Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today? Expert Opinion on Pharmacotherapy, 2024. 25(9): p. 1249-1263.
115. Zeng, X., et al., Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective. Frontiers in Pharmacology, 2025. 16: p. 1574385.
116. Liu, M. and Y. Wen, Point-of-care testing for early-stage liver cancer diagnosis and personalized medicine: Biomarkers, current technologies and perspectives. Heliyon, 2024. 10(19).
117. Szczepaniak, L.S., et al., Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. American Journal of Physiology-Endocrinology and Metabolism, 2005. 288(2): p. E462-E468.
118. Giulio Romanelli, R. and C. Stasi, Recent advancements in diagnosis and therapy of liver cirrhosis. Current drug targets, 2016. 17(15): p. 1804-1817.
119. Szabo, G. and F. Momen-Heravi, Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Nature reviews Gastroenterology & hepatology, 2017. 14(8): p. 455-466.
120. Park, C.C., et al., Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology, 2017. 152(3): p. 598-607. e2.
121. Hirsova, P., et al., Extracellular vesicles in liver pathobiology: small particles with big impact. Hepatology, 2016. 64(6): p. 2219-2233.
122. Ferro, A., et al., Extracellular vesicles as delivery vehicles for non-coding RNAs: potential biomarkers for chronic liver diseases. Biomolecules, 2024. 14(3): p. 277.
123. Righetti, R., et al., The role of noninvasive biomarkers for monitoring cell injury in advanced liver fibrosis. Expert Review of Gastroenterology & Hepatology, 2025. 19(1): p. 65-80.
124. Neuberger, J. and O. Cain, The need for alternatives to liver biopsies: non-invasive analytics and diagnostics. Hepatic Medicine: Evidence and Research, 2021: p. 59-69.
125. Srinivasa Babu, A., et al., Elastography in chronic liver disease: modalities, techniques, limitations, and future directions. Radiographics, 2016. 36(7): p. 1987-2006.
126. Laurent¹, S., et al., Liver Fibrosis by Vibration-Controlled Transient Elastography (Fibroscan®). Liver biopsy, 2011: p. 293.
127. Sebastiani, G., Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World journal of gastroenterology: WJG, 2009. 15(18): p. 2190.
128. Zhang, Y.N., et al., Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. Journal of Magnetic Resonance Imaging, 2020. 51(1): p. 25-42.
129. Dennis, A., et al., Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis. Frontiers in endocrinology, 2021. 11: p. 575843.
130. Gabriel-Medina, P., et al., Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level. Intern Emerg Med, 2024. 19(3): p. 745-756.
131. Wei, H. and B. Song, Elastography for Longitudinal Assessment of Liver Fibrosis after Antiviral Therapy: A Review. J Clin Transl Hepatol, 2020. 8(4): p. 445-453.
Downloads
Published
Issue
Section
Categories
- Clinical and Biomedical Sciences
- Ethics, Equity, and Social Justice in Health
- Health Systems and Policy
- Indigenous Knowledge and Culture
- Mental Health and Psychological Wellbeing
- Psychosocial and Behavioral Sciences
- Public Health
- Trauma, Conflict, and Humanitarian Health
- Pharmaceutical and Therapeutic Sciences
License
Copyright (c) 2026 Pan-African Journal of Health and Psychological Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles published in the Pan-African Journal of Health and Psychological Sciences (PAJHPS) are open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Under this license:
-
Authors retain copyright and grant the journal the right of first publication.
-
The work may be shared, copied, redistributed, and adapted for any purpose, even commercially.
-
Appropriate credit must be given to the original author(s) and the journal, along with a link to the license.
-
Users must indicate if changes were made.
-
There are no restrictions on reuse, provided the original work is properly cited.
Citation:
Authors and users must cite the original work in the following manner:
Author(s). (Year). Title of the article. Pan-African Journal of Health and Psychological Sciences, Volume(Issue), page range. https://doi.org/xx.xxxx/pajhps.vXnY.xxx
Copyright Statement:
Authors grant PAJHPS a non-exclusive license to publish the work and identify itself as the original publisher. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version (e.g., post it to a repository or publish it in a book), with acknowledgment of its initial publication in this journal.
